Current Headlines

  1. UNMC, Purdue Pharma Enter Partnership To Advance New Drug Development

    The University of Nebraska Medical Center (UNMC) and Purdue Pharma L.P., have entered into a partnership to advance graduate education and scientific research that could lead to new drug therapies for patients.

  2. SIGA Announces Completion Of Enrollment And Dosing In The Final Cohort Of Phase III Study Of TPOXX (Tecovirimat)

    SIGA Technologies, Inc. (SIGA) , a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, announced completion of enrollment and dosing in the second and final cohort of healthy subjects for the Phase III clinical study for its lead drug candidate, TPOXX (tecovirimat), for the treatment of orthopoxvirus infections

  3. TetraGenetics Announces Another Strategic Partnership With A Top Ten Pharmaceutical Company

    TetraGenetics Inc., an emerging biotechnology company engaged in the expression of ion channel drug targets, announced recently another new partnership with one of the world’s “top ten” pharmaceutical companies

  4. Takeda Announces Bold, New Access To Medicines Strategy

    Takeda Pharmaceutical Company Limited recently announced the launch of a bold, new Access to Medicines (AtM) strategy, aimed at increasing access to its innovative and potentially life-saving medicines for patients with some of the highest unmet medical needs

  5. FDA Accepts Clovis Oncology’s New Drug Application For Rucaparib For Priority Review For The Treatment Of Advanced Mutant BRCA Ovarian Cancer

    Clovis Oncology, Inc. announced recently that the U.S. Food and Drug Administration (FDA) has accepted Clovis’ New Drug Application (NDA) for accelerated approval of rucaparib and granted priority review status to the application with a Prescription Drug User Fee Act (PDUFA) date of February 23, 2017

  6. DeuteRx Enters Clinical Stage Development With DRX-065

    DeuteRx LLC, an R&D-focused biotechnology company dedicated to improving racemic small molecule marketed drugs and drug candidates, recently announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Company's investigational new drug (IND) application for DRX-065 (the deuterium-stabilized (R)-enantiomer of pioglitazone) and has determined that a Phase 1 clinical study in healthy volunteers can be initiated

  7. Phyton Biotech Achieves Manufacturing Milestone With Thapsigargin, The Active Agent In Mipsagargin

    Phyton Biotech recently announced that it has achieved a major milestone in connection with the manufacture of thapsigargin, an inhibitor derived from the Thapsia plant that is the active agent for the investigational prodrug mipsagargin

  8. FDA Approves TROXYCA ER (Oxycodone Hydrochloride And Naltrexone Hydrochloride) Extended-Release Capsules CII With Abuse-Deterrent Properties For The Management Of Pain

    Pfizer Inc. announced recently that the U.S. Food and Drug Administration (FDA) has approved TROXYCA ER (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules, for oral use, CII for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

  9. BeiGene Receives Approval To Initiate Clinical Trials In China With PARP Inhibitor BGB-290

    BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that it has received Clinical Trial Application (CTA) approval from the China Food and Drug Administration (CFDA) to conduct clinical trials in China with BGB-290, a highly potent and selective PARP inhibitor.

  10. Eleven Biotherapeutics Completes Exclusive Licensing Deal For IL-6 Antagonist Antibody Technology, Including EBI-031

    Eleven Biotherapeutics, Inc., a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, recently announced the effectiveness of the exclusive licensing deal with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (Roche)